Company intelligence / Profile preview

RockGene BioTech

Beijing, China

Ownership: Private
Development stage: Other

Overview

RocGene operates as a diagnostic equipment and reagent manufacturer rather than a clinical-stage drug development company. Products include quantitative PCR instruments, automatic nucleic acid extraction instruments, and related reagents. The company expanded significantly during COVID-19 pandemic response.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Molecular diagnostics equipment and reagentsNucleic acid extraction technology (magnetic bead method)Fluorescence quantitative PCR
Industry: Molecular Diagnostics

Partnerships

Zhongsheng Jienuo (China Bio Shanghai Jienuo Biotechnology Co., Ltd.)

Beyond the preview

Go deeper on RockGene BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RockGene BioTech.

Explore the full profile